No Announcements
Biocon operates across Generics (APIs and finished dosages), Biosimilars (through Biocon Biologics), and Research Services (Syngene) to expand access to affordable medicines globally . It serves 120+ countries through self-led and partner-led commercial models
Biosimilars contributed 58%, Research Services 23%, and Generics 19% in FY25.